Allan I. Goldberg

1.3k total citations
20 papers, 1.1k citations indexed

About

Allan I. Goldberg is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Geriatrics and Gerontology. According to data from OpenAlex, Allan I. Goldberg has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Cardiology and Cardiovascular Medicine, 7 papers in Endocrinology, Diabetes and Metabolism and 2 papers in Geriatrics and Gerontology. Recurrent topics in Allan I. Goldberg's work include Blood Pressure and Hypertension Studies (15 papers), Hormonal Regulation and Hypertension (7 papers) and Heart Failure Treatment and Management (3 papers). Allan I. Goldberg is often cited by papers focused on Blood Pressure and Hypertension Studies (15 papers), Hormonal Regulation and Hypertension (7 papers) and Heart Failure Treatment and Management (3 papers). Allan I. Goldberg collaborates with scholars based in United States, France and Hong Kong. Allan I. Goldberg's co-authors include Charles S. Sweet, Mary C. Dunlay, Karen E. Arcuri, Duane Snavely, Alan H. Gradman, Edward Nelson, Beth A. Soffer, J. Howard Pratt, Jackson T. Wright and Brian L. Wiens and has published in prestigious journals such as Hypertension, The American Journal of Cardiology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Allan I. Goldberg

20 papers receiving 996 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Allan I. Goldberg United States 17 908 526 94 90 85 20 1.1k
Brunner Hr Switzerland 13 761 0.8× 363 0.7× 77 0.8× 107 1.2× 269 3.2× 75 1.2k
Hiroshi Shionoiri Japan 17 732 0.8× 331 0.6× 106 1.1× 73 0.8× 130 1.5× 94 1.2k
Luc Poirier Canada 21 716 0.8× 309 0.6× 96 1.0× 143 1.6× 149 1.8× 71 1.2k
L. Terzoli Italy 15 572 0.6× 193 0.4× 74 0.8× 68 0.8× 122 1.4× 41 831
LE Ramsay United Kingdom 16 579 0.6× 287 0.5× 127 1.4× 77 0.9× 115 1.4× 53 1.2k
B. Waeber Switzerland 21 665 0.7× 272 0.5× 91 1.0× 135 1.5× 327 3.8× 67 1.3k
Gerd Bönner Germany 17 470 0.5× 247 0.5× 92 1.0× 110 1.2× 121 1.4× 82 886
Elí A. Ramírez Puerto Rico 6 878 1.0× 440 0.8× 86 0.9× 166 1.8× 68 0.8× 11 1.1k
P. Lazzari Italy 15 704 0.8× 324 0.6× 88 0.9× 54 0.6× 56 0.7× 30 903
R. Schmieder Germany 18 882 1.0× 390 0.7× 65 0.7× 107 1.2× 111 1.3× 59 1.3k

Countries citing papers authored by Allan I. Goldberg

Since Specialization
Citations

This map shows the geographic impact of Allan I. Goldberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan I. Goldberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan I. Goldberg more than expected).

Fields of papers citing papers by Allan I. Goldberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allan I. Goldberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan I. Goldberg. The network helps show where Allan I. Goldberg may publish in the future.

Co-authorship network of co-authors of Allan I. Goldberg

This figure shows the co-authorship network connecting the top 25 collaborators of Allan I. Goldberg. A scholar is included among the top collaborators of Allan I. Goldberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan I. Goldberg. Allan I. Goldberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldberg, Allan I., et al.. (2005). Investigation of Clinically Significant Change by Severity Level in College Counseling Center Clients. Journal of College Counseling. 8(2). 140–152. 18 indexed citations
2.
Flack, John M., Elijah Saunders, Alan H. Gradman, et al.. (2001). Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clinical Therapeutics. 23(8). 1193–1208. 53 indexed citations
3.
Oparil, Suzanne, Peter Aurup, Duane Snavely, & Allan I. Goldberg. (2001). Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. The American Journal of Cardiology. 87(6). 721–726. 20 indexed citations
4.
Azizi, Michel, Aleš Linhart, Joe Alexander, et al.. (2000). Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients. Journal of Hypertension. 18(8). 1139–1147. 60 indexed citations
5.
Paster, Robert Zorba, et al.. (1998). Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibitors. Clinical Therapeutics. 20(5). 978–989. 28 indexed citations
6.
Arcuri, Karen E., et al.. (1997). Comparative Antihypertensive Effects of Losartan 50 mg and Losartan 50 mg Titrated to 100 mg in Patients with Essential Hypertension. Blood Pressure. 6(1). 35–43. 48 indexed citations
7.
Ruilope, Luís M., et al.. (1996). Controlled Trial of Losartan Given Concomitantly with Different Doses of Hydrochlorothiazide in Hypertensive Patients. Blood Pressure. 5(1). 32–40. 64 indexed citations
8.
9.
10.
Mallion, Jean-Michel & Allan I. Goldberg. (1996). Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.. PubMed. 2. 82–6. 21 indexed citations
11.
Mallion, Jean‐Michel, et al.. (1995). Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension. Journal of Hypertension. 13(Supplement 1). S35–S41. 33 indexed citations
12.
Goldberg, Allan I. & C. Sweet. (1995). Efficacy and safety of losartan.. PubMed. 11 Suppl F. 27F–32F. 15 indexed citations
13.
Dunlay, Mary C., et al.. (1995). Losartan potassium as initial therapy in patients with severe hypertension.. PubMed. 9(11). 861–7. 18 indexed citations
14.
Goldberg, Allan I., Mary C. Dunlay, & Charles S. Sweet. (1995). Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors. Journal of Hypertension. 13(Supplement 1). S77–S80. 20 indexed citations
15.
Gradman, Alan H., Karen E. Arcuri, Allan I. Goldberg, et al.. (1995). A Randomized, Placebo-Controlled, Double-Blind, Parallel Study of Various Doses of Losartan Potassium Compared With Enalapril Maleate in Patients With Essential Hypertension. Hypertension. 25(6). 1345–1350. 185 indexed citations
16.
17.
Dahlöf, Björn, et al.. (1995). Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension*. American Journal of Hypertension. 8(6). 578–583. 76 indexed citations
18.
Chan, Juliana C.N., Julia Critchley, Salmo Raskin, et al.. (1995). Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.. PubMed. 9(9). 765–71. 38 indexed citations
19.
Soffer, Beth A., Jackson T. Wright, J. Howard Pratt, et al.. (1995). Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension. Hypertension. 26(1). 112–117. 123 indexed citations
20.
Weber, Michael A., Allan I. Goldberg, Elizabeth P. Faison, et al.. (1994). Extended-release felodipine in patients with mild to moderate hypertension. Clinical Pharmacology & Therapeutics. 55(3). 346–352. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brunner Hr Breakdown of academic impact, for papers by Hiroshi Shionoiri Breakdown of academic impact, for papers by Luc Poirier Breakdown of academic impact, for papers by L. Terzoli Breakdown of academic impact, for papers by LE Ramsay Breakdown of academic impact, for papers by B. Waeber Breakdown of academic impact, for papers by Gerd Bönner Breakdown of academic impact, for papers by Elí A. Ramírez Breakdown of academic impact, for papers by P. Lazzari Breakdown of academic impact, for papers by R. Schmieder
Rankless by CCL
2026